United States: Update On CRISPR Patent Battle

Discovery of the revolutionary gene editing technology called CRISPR touched off a battle between the University of California (UC) and the Broad Institute (Broad) over control of the associated patent rights. The technology evolved out of research findings that the CRISPR-Cas 9 immune system of prokaryotes (e.g., bacteria) could be harnessed as a gene editing tool with widespread potential commercial applications in the fields of medicine and agriculture.

UC and Broad both filed initial patent applications prior to the effective date of the prior art provisions of the AIA, making their applications subject to pre-AIA law regarding priority of invention. One year ago, on January 11, and at the suggestion of UC, the PTAB declared an interference between UC's pending patent application and a series of patents issued to Broad covering CRISPR technology (interference no. 106,048). UC filed its initial patent application first and also published a preliminary report several months prior to Broad's earliest filing date. However, Broad used the priority examination option at the USPTO to move its applications more quickly to grant. 

The claims of the Broad patents relate to use of CRISPR in eukaryotic cells, i.e., cells having a nucleus such as plant or animal cells. UC's pending claims do not recite a specific cell environment, and thus cover the use of CRISPR in either eukaryotic or prokaryotic cells. The PTAB's declaration of interference identified the interfering subject matter (i.e., the count) as the use of CRISPR in eukaryotic cells. 

Over the past year, the parties proposed motions in the PTAB on various matters related to the priority contest, as well as the patentability or enforceability of the opposing party's claims. During the initial stage of the contest, however, the PTAB has confined the proceedings to the parties' positions on issues that impact the priority contest, such as whether an interference-in-fact existed, the benefit of priority claims, and the definition of the count. On December 6, 2016, the PTAB heard oral arguments on these issues.

A central issue in the interference concerns whether Broad's claims to CRISPR in eukaryotic cells cover a separate invention from UC's claims that do not specify a particular cell environment. If so, then no interference-in-fact would exist and the PTAB would be expected to dissolve the interference. 

Broad argues that the conditions for an interference-in-fact under the two-way test of 37 C.F.R. §41.203(a) are not satisfied because UC's claims do not anticipate or render obvious its claims to CRISPR in eukaryotic cells. According to Broad, the skilled artisan would not have had a reasonable expectation of successfully adapting the UC's published techniques to eukaryotic cells and therefore its claims would not have been obvious over UC's claims and prior publication. UC argues to the contrary and that for the same reason the eukaryotic limitation should be removed from the definition of the count. Doing so would permit UC to rely on its best proofs of earlier invention.

The PTAB now faces the challenge of assessing the competing positions and sorting through the voluminous evidence that includes conflicting interpretations of inventor statements, patent filings from other competing laboratories, and highly technical scientific studies or opinions that are purported to show the relative ease or difficulty of translating techniques developed in prokaryotic to eukaryotic cells. While no firm conclusions can be drawn at this stage, news reports from the December 6 hearing suggest that UC arguments received more scrutiny and probing by the PTAB judges than those of Broad.

If the PTAB were to decide that no interference-in-fact exists and dissolves the interference, Broad would exit with its patents claiming CRISPR in eukaryotic cells and UC's application would return to the examiner for further prosecution.  Since many of UC's claims have been allowed, those claims could presumably proceed to issuance.  Also, UC's allowed claims are generic to the cell environment, so an end to the interference should not itself deprive UC of patent rights to certain CRISPR uses in eukaryotic cells. 

An end to the interference, however, would not necessarily signal an end to the battle over CRISPR. Any granted claims could still be subject to a validity challenge by some form of post-grant proceeding. The PTAB deferred any decision on proposed motions by both UC and Broad on various validity issues that could be revisited in another forum. 

If the PTAB were to maintain the interference, the priority contest could continue based on the current count or one of the modified counts suggested by UC. The PTAB could also decide to entertain the patentability or enforceability motions proposed in the first stage of the interference.

Whatever the outcome of the ongoing interference, licensees of the CRISPR technology should expect continued uncertainty over the patent landscape for the foreseeable future, absent a settlement between the parties. 

The patent battle over CRISPR also highlights the risks associated with publicly disclosing ground-breaking results when the potentially most valuable applications have yet to be fully reduced to practice. In this case, the initial publication of results outside the eukaryotic cell environment may have altered the competitive playing field among the research groups in the CRISPR field. The current interference might have been avoided or decided on different terms had the initial public disclosures followed, rather than preceded, the successful application of CRISPR to eukaryotic cells.

This article is intended to provide information of general interest to the public and is not intended to offer legal advice about specific situations or problems. Brinks Gilson & Lione does not intend to create an attorney-client relationship by offering this information and review of the information shall not be deemed to create such a relationship. You should consult a lawyer if you have a legal matter requiring attention. For further information, please contact a Brinks Gilson & Lione lawyer.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions